PureTech Health plc (PRTC) 10-Year Financial Performance & Capital Metrics

PRTC •

HealthcareBiotechnologyDrug Discovery and Antibody Platforms

AboutPureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Show more

Revenue $5M +45.0%
EBITDA -$133M +6.2%
Net Income $54M +181.4%
EPS (Diluted) 2.00 +183.3%
Gross Margin 26.04% +154.1%
EBITDA Margin -2744.9% +35.3%
Operating Margin -2818.87% +35.8%
Net Margin 1108.33% +156.2%
ROE 12.36% +194.6%
ROIC -46.17% -55.2%
Debt/Equity 0.05 -0.9%
Interest Coverage -13.56 -25.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Share count reduced 2.4% through buybacks
✓Trading at only 1.1x book value

✗Weaknesses

✗Profits declining 33.8% over 5 years
✗Negative free cash flow
✗Sales declining 11.1% over 5 years
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y9.15%

5Y-11.09%

3Y-21.5%

TTM-79.43%

Profit (Net Income) CAGR

10Y-

5Y-33.81%

3Y-

TTM48.81%

EPS CAGR

10Y-

5Y-32.62%

3Y-

TTM40.91%

ROCE

10Y Avg-45.34%

5Y Avg-22.07%

3Y Avg-25.29%

Latest-22.61%

Peer Comparison

Drug Discovery and Antibody Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
REGNRegeneron Pharmaceuticals, Inc.	107.56B	781.67	18.84	0.99%	31.41%	14.41%	3.79%	0.09
CTMXCytomX Therapeutics, Inc.	430.14M	5.37	14.13	36.45%	24.66%	26.09%
PRTCPureTech Health plc	405.3M	16.77	8.39	44.98%	-495.91%	-8.53%		0.05
DNAGinkgo Bioworks Holdings, Inc.	327.53M	6.75	-1.20	-25.06%	-183.81%	-61.5%		0.82
BCYCBicycle Therapeutics plc	111.38M	5.73	-1.98	30.76%	-8.85%	-40.53%		0.01
CCCCC4 Therapeutics, Inc.	261.67M	2.70	-2.13	-100%		-40.92%		0.23
MOLNMolecular Partners AG	187.84M	5.02	-2.43	-29.38%	-10.87%	-63.06%		0.02
RXRXRecursion Pharmaceuticals, Inc.	1.94B	3.67	-2.55	26.92%	-8.65%	-57.01%		0.07

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	11.74M	4.43M	650K	16.37M	8.69M	8.34M	9.98M	2.09M	3.33M	4.83M
Revenue Growth %	483.5%	-62.26%	-85.33%	2418.62%	-46.93%	-3.99%	19.64%	-79.06%	59.33%	44.98%
Cost of Goods Sold+	740K	1.57M	71.03M	77.4M	85.85M	0	110.47M	152.43M	4.93M	0
COGS % of Revenue	6.3%	35.43%	10928.46%	472.8%	988.12%	-	1107.03%	7293.44%	148.14%	-
Gross Profit+	11M	2.86M	-70.39M	-61.03M	-77.16M	8.34M	-100.49M	-136.81M	-1.6M	1.26M
Gross Margin %	93.7%	64.57%	-10828.46%	-372.8%	-888.12%	100%	-1007.03%	-6546.17%	-48.14%	26.04%
Gross Profit Growth %	446.72%	-73.99%	-2560.15%	13.29%	-26.43%	110.81%	-1304.8%	-36.15%	98.83%	178.42%
Operating Expenses+	55.38M	78.36M	116.07M	120.39M	144.09M	127.87M	160.26M	60.99M	54.55M	140.41M
OpEx % of Revenue	471.74%	1768.45%	17856.92%	735.39%	1658.46%	1533.05%	1605.99%	2918.28%	1638.26%	2908.24%
Selling, General & Admin	18.38M	37.16M	46.28M	24.43M	34.89M	26.5M	30.76M	35.67M	48.36M	27.49M
SG&A % of Revenue	156.54%	838.52%	7120.46%	149.2%	401.59%	317.67%	308.26%	1706.65%	1452.31%	569.41%
Research & Development	13.41M	41.2M	71.67M	57.29M	65.17M	61.19M	81.52M	116.11M	96.23M	54.28M
R&D % of Revenue	114.21%	929.93%	11026.46%	349.97%	750.07%	733.56%	816.93%	5555.65%	2889.94%	1124.28%
Other Operating Expenses	448K	46K	14K	-278K	44.03M	40.19M	47.98M	-90.79M	-90.04M	58.64M
Operating Income+	-43.64M	-73.93M	-115.42M	-104.02M	-135.4M	-119.53M	-150.28M	-197.81M	-146.2M	-136.09M
Operating Margin %	-371.74%	-1668.45%	-17756.92%	-635.39%	-1558.46%	-1433.05%	-1505.98%	-9464.45%	-4390.36%	-2818.87%
Operating Income Growth %	-150.17%	-69.4%	-56.12%	9.88%	-30.17%	11.72%	-25.73%	-31.62%	26.09%	6.91%
EBITDA+	-42.9M	-72.36M	-113.32M	-101.24M	-128.73M	-112.88M	-143.04M	-188.91M	-141.27M	-132.52M
EBITDA Margin %	-365.43%	-1633.02%	-17434%	-618.42%	-1481.74%	-1353.27%	-1433.45%	-9038.95%	-4242.22%	-2744.9%
EBITDA Growth %	-152.51%	-68.66%	-56.61%	10.66%	-27.16%	12.32%	-26.73%	-32.07%	25.22%	6.19%
D&A (Non-Cash Add-back)	740K	1.57M	2.1M	2.78M	6.67M	6.66M	7.24M	8.89M	4.93M	3.57M
EBIT	-51.97M	-76.37M	-70.01M	-68.05M	481.12M	56.03M	19.46M	-197.81M	-16.56M	33.81M
Net Interest Income+	-4.09M	-5.62M	-8.46M	-11.45M	260K	-1.76M	-4.5M	1.85M	2.52M	12.63M
Interest Income	262K	1.19M	1.75M	3.36M	4.36M	1.18M	214K	5.8M	16.01M	22.67M
Interest Expense	4.35M	6.81M	10.21M	14.81M	4.1M	2.95M	4.71M	3.95M	13.49M	10.04M
Other Income/Expense	-12.68M	-9.25M	44.71M	35.58M	613.87M	138.5M	91.33M	105.02M	110.1M	159.87M
Pretax Income+	-56.32M	-83.18M	-70.71M	-68.44M	478.47M	18.97M	-58.95M	-92.78M	-36.1M	23.77M
Pretax Margin %	-479.73%	-1877.27%	-10878.62%	-418.04%	5507.3%	227.42%	-590.77%	-4439.38%	-1084.17%	492.42%
Income Tax+	1.92M	-1.57M	-14K	2.22M	112.41M	14.4M	3.76M	-55.72M	30.52M	-4.01M
Effective Tax Rate %	69.95%	58.66%	-43.66%	63.79%	88.02%	31.55%	102.72%	54.27%	181.97%	225.08%
Net Income+	-39.39M	-48.79M	30.87M	-43.65M	421.14M	5.99M	-60.56M	-50.35M	-65.7M	53.51M
Net Margin %	-335.55%	-1101.15%	4749.08%	-266.65%	4847.42%	71.75%	-606.85%	-2409.33%	-1972.88%	1108.33%
Net Income Growth %	5.4%	-23.86%	163.27%	-241.42%	1064.73%	-98.58%	-1111.83%	16.85%	-30.47%	181.45%
Net Income (Continuing)	-58.24M	-81.61M	-57.49M	-70.66M	335.27M	4.57M	-62.71M	-37.06M	-66.63M	27.78M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	-62.07M	-85.25M	-150.31M	-108.53M	-17.64M	-16.21M	-9.37M	5.37M	-5.83M	-6.77M
EPS (Diluted)+	-2.10	-2.10	1.10	-1.60	14.40	0.20	-2.10	-1.80	-2.40	2.00
EPS Growth %	58.82%	0%	152.38%	-245.45%	1000%	-98.61%	-1150%	14.29%	-33.33%	183.33%
EPS (Basic)	-2.10	-2.10	1.10	-1.60	14.90	0.20	-2.10	-1.80	-2.40	2.00
Diluted Shares Outstanding	18.53M	22.95M	23.89M	27.38M	29.18M	29.29M	28.66M	28.48M	27.63M	26.97M
Basic Shares Outstanding	18.53M	22.95M	24.07M	27.28M	29.25M	29.93M	28.66M	27.97M	27.63M	26.97M
Dividend Payout Ratio	-	-	0.29%	-	0.03%	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	318.2M	288.15M	198.11M	259.79M	168.84M	414.35M	501.81M	386.19M	347.2M	386.26M
Cash & Short-Term Investments	314.53M	282.37M	189.67M	250.88M	162.45M	403.88M	465.71M	350.1M	327.14M	367.31M
Cash Only	134.75M	62.96M	72.65M	117.05M	132.36M	403.88M	465.71M	149.87M	191.08M	280.64M
Short-Term Investments	179.78M	219.41M	117.03M	133.83M	30.09M	0	0	200.23M	136.06M	86.67M
Accounts Receivable	706K	125K	1.8M	1.33M	2.33M	2.94M	3.59M	22.36M	2.38M	12.9M
Days Sales Outstanding	21.95	10.3	1.01K	29.61	97.76	128.61	131.27	3.9K	260.43	975.48
Inventory	0	-1.92M	-2.72M	-1.33M	0	0	28M	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	92.51	-	-	-
Other Current Assets	896K	897K	927K	2.2M	2.12M	2.12M	-6.24M	2.12M	13.37M	1.64M
Total Non-Current Assets+	8.55M	10.6M	141.74M	181.98M	772.33M	575.64M	444.2M	316.45M	346.77M	216.38M
Property, Plant & Equipment	4.52M	6.92M	6.86M	8.32M	43.84M	42.87M	43.94M	37.24M	19.36M	15.13M
Fixed Asset Turnover	2.60x	0.64x	0.09x	1.97x	0.20x	0.19x	0.23x	0.06x	0.17x	0.32x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	3.87M	3.52M	3.31M	3.08M	625K	899K	987K	831K	906K	601K
Long-Term Investments	-179.68M	-219.32M	14.33M	35.93M	695.46M	531.86M	398.46M	60.81M	325.63M	200.17M
Other Non-Current Assets	57K	65K	117.1M	134.2M	32.27M	531.87M	399.27M	278.38M	879K	476K
Total Assets+	326.75M	298.75M	339.85M	441.76M	941.18M	989.99M	946.01M	702.65M	693.97M	602.63M
Asset Turnover	0.04x	0.01x	0.00x	0.04x	0.01x	0.01x	0.01x	0.00x	0.00x	0.01x
Asset Growth %	43.3%	-8.57%	13.76%	29.99%	113.05%	5.19%	-4.44%	-25.72%	-1.23%	-13.16%
Total Current Liabilities+	160.52M	204.08M	273.86M	265.76M	139.2M	180.92M	226.13M	96.89M	51.37M	41.39M
Accounts Payable	2.39M	2.08M	3.39M	4.64M	11.1M	8.87M	11.35M	26.5M	14.64M	5.52M
Days Payables Outstanding	1.18K	482.87	17.44	21.9	47.19	-	37.48	63.46	1.08K	-
Short-Term Debt	4.96M	6.95M	7.46M	12.01M	1.46M	26.45M	5.5M	7.5M	3.7M	4.11M
Deferred Revenue (Current)	87.05M	88.38M	129.01M	30.8M	22.21M	141.61M	31.32M	2.19M	-29.47M	0
Other Current Liabilities	61.29M	97.62M	121.04M	207.08M	92.45M	-529K	152.01M	29.4M	29.64M	27.18M
Current Ratio	1.98x	1.41x	0.72x	0.98x	1.21x	2.29x	2.22x	3.99x	6.76x	9.33x
Quick Ratio	1.98x	1.42x	0.73x	0.98x	1.21x	2.29x	2.10x	3.99x	6.76x	9.33x
Cash Conversion Cycle	-	-	-	-	-	-	186.3	-	-	-
Total Non-Current Liabilities+	2.18M	2.26M	1.99M	9.03M	151.58M	155.53M	135.72M	58.17M	184.37M	153.31M
Long-Term Debt	0	0	0	357K	0	14.82M	14.26M	10.24M	0	0
Capital Lease Obligations	0	0	410K	357K	34.91M	32.09M	29.04M	24.16M	18.25M	14.67M
Deferred Tax Liabilities	0	0	4.4M	6.43M	115.44M	108.63M	89.77M	19.64M	52.46M	0
Other Non-Current Liabilities	1.89M	2.06M	1.42M	876K	0	-1K	2.66M	4.13M	113.66M	138.64M
Total Liabilities	162.7M	206.34M	275.85M	274.79M	290.78M	336.45M	361.86M	155.06M	235.74M	194.7M
Total Debt+	4.96M	6.95M	7.46M	12.37M	39.3M	76.62M	52.75M	46.87M	25.34M	22.36M
Net Debt	-129.8M	-56.01M	-65.19M	-104.68M	-93.06M	-327.26M	-413.68M	-102.99M	-165.74M	-258.28M
Debt / Equity	0.03x	0.08x	0.12x	0.07x	0.06x	0.12x	0.09x	0.09x	0.06x	0.05x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-10.03x	-10.86x	-11.30x	-7.03x	-33.01x	-40.57x	-31.88x	-50.04x	-10.84x	-13.56x
Total Equity+	164.05M	92.41M	64M	166.97M	650.4M	653.54M	584.15M	547.59M	458.23M	407.93M
Equity Growth %	22.71%	-43.67%	-30.75%	160.91%	289.53%	0.48%	-10.62%	-6.26%	-16.32%	-10.98%
Book Value per Share	8.85	4.03	2.68	6.10	22.29	22.32	20.38	19.23	16.58	15.13
Total Shareholders' Equity	226.12M	177.67M	214.3M	275.51M	668.04M	669.75M	593.51M	542.22M	464.07M	414.71M
Common Stock	4.52M	4.61M	4.68M	5.38M	5.41M	5.42M	5.44M	5.46M	5.46M	4.86M
Retained Earnings	-111.42M	-160.34M	-127.87M	-167.69M	254.44M	260.43M	199.87M	149.52M	83.82M	32.49M
Treasury Stock	0	0	0	0	0	0	0	-26.49M	-44.63M	-46.86M
Accumulated OCI	-1.05M	-2.24M	-3.88M	-6.07M	-18.28M	-23.58M	-39.61M	-14.39M	129.15M	133.96M
Minority Interest	-62.07M	-85.25M	-150.31M	-108.53M	-17.64M	-16.21M	-9.37M	5.37M	-5.83M	-6.77M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-28.61M	-58.03M	-88.69M	-72.8M	-98.16M	-131.83M	-158.27M	-178.79M	-105.92M	-134.37M
Operating CF Margin %	-243.71%	-1309.7%	-13644.31%	-444.66%	-1129.79%	-1580.47%	-1586.07%	-8554.64%	-3180.69%	-2783.12%
Operating CF Growth %	-171.37%	-102.83%	-52.82%	17.92%	-34.84%	-34.3%	-20.06%	-12.96%	40.76%	-26.86%
Net Income	-58.24M	-81.61M	-70.7M	-70.66M	366.06M	4.57M	-62.71M	-37.06M	-65.7M	27.78M
Depreciation & Amortization	740K	1.57M	2.1M	2.78M	6.67M	6.64M	7.29M	8.89M	4.93M	3.57M
Stock-Based Compensation	11.1M	10.15M	11.85M	12.64M	14.47M	10.72M	13.95M	14.7M	4.42M	22.85M
Deferred Taxes	-383K	-783K	-116.81M	-19.42M	-546.61M	-151.35M	-112.61M	-70.12M	0	0
Other Non-Cash Items	13.37M	10.7M	81.9M	-8.1M	46.23M	6.11M	-5.05M	-111.12M	-67.09M	-178.34M
Working Capital Changes	4.81M	1.94M	2.97M	9.96M	15.03M	-8.53M	861K	15.92M	17.52M	-10.24M
Change in Receivables	1.11M	581K	-1.67M	467K	747K	-529K	-617K	-7.73M	9.75M	629K
Change in Inventory	0	0	0	0	0	0	-103K	0	0	0
Change in Payables	4.32M	3.52M	5.24M	5.09M	11.17M	605K	8.34M	22.03M	3.84M	-9.7M
Cash from Investing+	-184.24M	-43.23M	83.68M	-39.65M	63.66M	364.48M	197.38M	-107.22M	68.99M	240.89M
Capital Expenditures	-4.61M	-3.68M	-2.17M	-4.49M	-12.54M	-5.42M	-5.66M	-2.18M	-245K	-11K
CapEx % of Revenue	39.27%	82.96%	334%	27.43%	144.31%	65.03%	56.73%	104.11%	7.36%	0.23%
Acquisitions	1.16M	0	-16.34M	-13.39M	-16.04M	-10M	321K	-20.44M	-13.78M	-105.97M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-1.16M	-39.55M	-16.34M	125K	191K	350K	-14.91M	416K	865K	255K
Cash from Financing+	285.94M	29.49M	14.7M	156.89M	49.91M	38.87M	22.73M	-29.83M	78.14M	-16.96M
Debt Issued (Net)	1.48M	2.33M	2.45M	5.96M	1.43M	39.79M	2.21M	393K	-3.34M	-3.39M
Equity Issued (Net)	0	0	1000K	-35K	1000K	1000K	-1000K	-1000K	-1000K	-1000K
Dividends Paid	0	0	-91K	-8K	-112K	0	0	0	0	0
Share Repurchases	0	0	-66K	-35K	-1.28M	0	0	-26.49M	-19.65M	-107.56M
Other Financing	284.46M	27.16M	0	150.96M	-1.68M	-2.91M	33.84M	-4.07M	99.98M	93.1M
Net Change in Cash	72.79M	-71.79M	9.69M	44.4M	15.31M	271.52M	61.83M	-315.84M	41.22M	89.56M
Free Cash Flow+	-33.22M	-61.71M	-90.86M	-77.29M	-110.69M	-137.25M	-163.94M	-180.97M	-106.16M	-134.38M
FCF Margin %	-282.97%	-1392.67%	-13978.31%	-472.09%	-1274.1%	-1645.5%	-1642.8%	-8658.76%	-3188.05%	-2783.35%
FCF Growth %	-203.03%	-85.75%	-47.24%	14.94%	-43.23%	-23.99%	-19.44%	-10.39%	41.34%	-26.58%
FCF per Share	-1.79	-2.69	-3.80	-2.82	-3.79	-4.69	-5.72	-6.36	-3.84	-4.98
FCF Conversion (FCF/Net Income)	0.73x	1.19x	-2.87x	1.67x	-0.23x	-22.03x	2.61x	3.55x	1.61x	-2.51x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-26.46%	-38.05%	39.47%	-37.8%	103.05%	0.92%	-9.79%	-8.9%	-13.06%	12.36%
Return on Invested Capital (ROIC)	-95.55%	-156.94%	-491.73%	-255.4%	-32.78%	-20.29%	-45.31%	-48.18%	-29.75%	-46.17%
Gross Margin	93.7%	64.57%	-10828.46%	-372.8%	-888.12%	100%	-1007.03%	-6546.17%	-48.14%	26.04%
Net Margin	-335.55%	-1101.15%	4749.08%	-266.65%	4847.42%	71.75%	-606.85%	-2409.33%	-1972.88%	1108.33%
Debt / Equity	0.03x	0.08x	0.12x	0.07x	0.06x	0.12x	0.09x	0.09x	0.06x	0.05x
Interest Coverage	-10.03x	-10.86x	-11.30x	-7.03x	-33.01x	-40.57x	-31.88x	-50.04x	-10.84x	-13.56x
FCF Conversion	0.73x	1.19x	-2.87x	1.67x	-0.23x	-22.03x	2.61x	3.55x	1.61x	-2.51x
Revenue Growth	483.5%	-62.26%	-85.33%	2418.62%	-46.93%	-3.99%	19.64%	-79.06%	59.33%	44.98%

US Stock Screener

...

PureTech Health plc (PRTC) 10-Year Financial Performance & Capital Metrics

PRTC •

HealthcareBiotechnologyDrug Discovery and Antibody Platforms

Revenue $5M +45.0%
EBITDA -$133M +6.2%
Net Income $54M +181.4%
EPS (Diluted) 2.00 +183.3%
Gross Margin 26.04% +154.1%
EBITDA Margin -2744.9% +35.3%
Operating Margin -2818.87% +35.8%
Net Margin 1108.33% +156.2%
ROE 12.36% +194.6%
ROIC -46.17% -55.2%
Debt/Equity 0.05 -0.9%
Interest Coverage -13.56 -25.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Share count reduced 2.4% through buybacks
✓Trading at only 1.1x book value

✗Weaknesses

✗Profits declining 33.8% over 5 years
✗Negative free cash flow
✗Sales declining 11.1% over 5 years
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y9.15%

5Y-11.09%

3Y-21.5%

TTM-79.43%

Profit (Net Income) CAGR

10Y-

5Y-33.81%

3Y-

TTM48.81%

EPS CAGR

10Y-

5Y-32.62%

3Y-

TTM40.91%

ROCE

10Y Avg-45.34%

5Y Avg-22.07%

3Y Avg-25.29%

Latest-22.61%

Peer Comparison

Drug Discovery and Antibody Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
REGNRegeneron Pharmaceuticals, Inc.	107.56B	781.67	18.84	0.99%	31.41%	14.41%	3.79%	0.09
CTMXCytomX Therapeutics, Inc.	430.14M	5.37	14.13	36.45%	24.66%	26.09%
PRTCPureTech Health plc	405.3M	16.77	8.39	44.98%	-495.91%	-8.53%		0.05
DNAGinkgo Bioworks Holdings, Inc.	327.53M	6.75	-1.20	-25.06%	-183.81%	-61.5%		0.82
BCYCBicycle Therapeutics plc	111.38M	5.73	-1.98	30.76%	-8.85%	-40.53%		0.01
CCCCC4 Therapeutics, Inc.	261.67M	2.70	-2.13	-100%		-40.92%		0.23
MOLNMolecular Partners AG	187.84M	5.02	-2.43	-29.38%	-10.87%	-63.06%		0.02
RXRXRecursion Pharmaceuticals, Inc.	1.94B	3.67	-2.55	26.92%	-8.65%	-57.01%		0.07

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	11.74M	4.43M	650K	16.37M	8.69M	8.34M	9.98M	2.09M	3.33M	4.83M
Revenue Growth %	483.5%	-62.26%	-85.33%	2418.62%	-46.93%	-3.99%	19.64%	-79.06%	59.33%	44.98%
Cost of Goods Sold+	740K	1.57M	71.03M	77.4M	85.85M	0	110.47M	152.43M	4.93M	0
COGS % of Revenue	6.3%	35.43%	10928.46%	472.8%	988.12%	-	1107.03%	7293.44%	148.14%	-
Gross Profit+	11M	2.86M	-70.39M	-61.03M	-77.16M	8.34M	-100.49M	-136.81M	-1.6M	1.26M
Gross Margin %	93.7%	64.57%	-10828.46%	-372.8%	-888.12%	100%	-1007.03%	-6546.17%	-48.14%	26.04%
Gross Profit Growth %	446.72%	-73.99%	-2560.15%	13.29%	-26.43%	110.81%	-1304.8%	-36.15%	98.83%	178.42%
Operating Expenses+	55.38M	78.36M	116.07M	120.39M	144.09M	127.87M	160.26M	60.99M	54.55M	140.41M
OpEx % of Revenue	471.74%	1768.45%	17856.92%	735.39%	1658.46%	1533.05%	1605.99%	2918.28%	1638.26%	2908.24%
Selling, General & Admin	18.38M	37.16M	46.28M	24.43M	34.89M	26.5M	30.76M	35.67M	48.36M	27.49M
SG&A % of Revenue	156.54%	838.52%	7120.46%	149.2%	401.59%	317.67%	308.26%	1706.65%	1452.31%	569.41%
Research & Development	13.41M	41.2M	71.67M	57.29M	65.17M	61.19M	81.52M	116.11M	96.23M	54.28M
R&D % of Revenue	114.21%	929.93%	11026.46%	349.97%	750.07%	733.56%	816.93%	5555.65%	2889.94%	1124.28%
Other Operating Expenses	448K	46K	14K	-278K	44.03M	40.19M	47.98M	-90.79M	-90.04M	58.64M
Operating Income+	-43.64M	-73.93M	-115.42M	-104.02M	-135.4M	-119.53M	-150.28M	-197.81M	-146.2M	-136.09M
Operating Margin %	-371.74%	-1668.45%	-17756.92%	-635.39%	-1558.46%	-1433.05%	-1505.98%	-9464.45%	-4390.36%	-2818.87%
Operating Income Growth %	-150.17%	-69.4%	-56.12%	9.88%	-30.17%	11.72%	-25.73%	-31.62%	26.09%	6.91%
EBITDA+	-42.9M	-72.36M	-113.32M	-101.24M	-128.73M	-112.88M	-143.04M	-188.91M	-141.27M	-132.52M
EBITDA Margin %	-365.43%	-1633.02%	-17434%	-618.42%	-1481.74%	-1353.27%	-1433.45%	-9038.95%	-4242.22%	-2744.9%
EBITDA Growth %	-152.51%	-68.66%	-56.61%	10.66%	-27.16%	12.32%	-26.73%	-32.07%	25.22%	6.19%
D&A (Non-Cash Add-back)	740K	1.57M	2.1M	2.78M	6.67M	6.66M	7.24M	8.89M	4.93M	3.57M
EBIT	-51.97M	-76.37M	-70.01M	-68.05M	481.12M	56.03M	19.46M	-197.81M	-16.56M	33.81M
Net Interest Income+	-4.09M	-5.62M	-8.46M	-11.45M	260K	-1.76M	-4.5M	1.85M	2.52M	12.63M
Interest Income	262K	1.19M	1.75M	3.36M	4.36M	1.18M	214K	5.8M	16.01M	22.67M
Interest Expense	4.35M	6.81M	10.21M	14.81M	4.1M	2.95M	4.71M	3.95M	13.49M	10.04M
Other Income/Expense	-12.68M	-9.25M	44.71M	35.58M	613.87M	138.5M	91.33M	105.02M	110.1M	159.87M
Pretax Income+	-56.32M	-83.18M	-70.71M	-68.44M	478.47M	18.97M	-58.95M	-92.78M	-36.1M	23.77M
Pretax Margin %	-479.73%	-1877.27%	-10878.62%	-418.04%	5507.3%	227.42%	-590.77%	-4439.38%	-1084.17%	492.42%
Income Tax+	1.92M	-1.57M	-14K	2.22M	112.41M	14.4M	3.76M	-55.72M	30.52M	-4.01M
Effective Tax Rate %	69.95%	58.66%	-43.66%	63.79%	88.02%	31.55%	102.72%	54.27%	181.97%	225.08%
Net Income+	-39.39M	-48.79M	30.87M	-43.65M	421.14M	5.99M	-60.56M	-50.35M	-65.7M	53.51M
Net Margin %	-335.55%	-1101.15%	4749.08%	-266.65%	4847.42%	71.75%	-606.85%	-2409.33%	-1972.88%	1108.33%
Net Income Growth %	5.4%	-23.86%	163.27%	-241.42%	1064.73%	-98.58%	-1111.83%	16.85%	-30.47%	181.45%
Net Income (Continuing)	-58.24M	-81.61M	-57.49M	-70.66M	335.27M	4.57M	-62.71M	-37.06M	-66.63M	27.78M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	-62.07M	-85.25M	-150.31M	-108.53M	-17.64M	-16.21M	-9.37M	5.37M	-5.83M	-6.77M
EPS (Diluted)+	-2.10	-2.10	1.10	-1.60	14.40	0.20	-2.10	-1.80	-2.40	2.00
EPS Growth %	58.82%	0%	152.38%	-245.45%	1000%	-98.61%	-1150%	14.29%	-33.33%	183.33%
EPS (Basic)	-2.10	-2.10	1.10	-1.60	14.90	0.20	-2.10	-1.80	-2.40	2.00
Diluted Shares Outstanding	18.53M	22.95M	23.89M	27.38M	29.18M	29.29M	28.66M	28.48M	27.63M	26.97M
Basic Shares Outstanding	18.53M	22.95M	24.07M	27.28M	29.25M	29.93M	28.66M	27.97M	27.63M	26.97M
Dividend Payout Ratio	-	-	0.29%	-	0.03%	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	318.2M	288.15M	198.11M	259.79M	168.84M	414.35M	501.81M	386.19M	347.2M	386.26M
Cash & Short-Term Investments	314.53M	282.37M	189.67M	250.88M	162.45M	403.88M	465.71M	350.1M	327.14M	367.31M
Cash Only	134.75M	62.96M	72.65M	117.05M	132.36M	403.88M	465.71M	149.87M	191.08M	280.64M
Short-Term Investments	179.78M	219.41M	117.03M	133.83M	30.09M	0	0	200.23M	136.06M	86.67M
Accounts Receivable	706K	125K	1.8M	1.33M	2.33M	2.94M	3.59M	22.36M	2.38M	12.9M
Days Sales Outstanding	21.95	10.3	1.01K	29.61	97.76	128.61	131.27	3.9K	260.43	975.48
Inventory	0	-1.92M	-2.72M	-1.33M	0	0	28M	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	92.51	-	-	-
Other Current Assets	896K	897K	927K	2.2M	2.12M	2.12M	-6.24M	2.12M	13.37M	1.64M
Total Non-Current Assets+	8.55M	10.6M	141.74M	181.98M	772.33M	575.64M	444.2M	316.45M	346.77M	216.38M
Property, Plant & Equipment	4.52M	6.92M	6.86M	8.32M	43.84M	42.87M	43.94M	37.24M	19.36M	15.13M
Fixed Asset Turnover	2.60x	0.64x	0.09x	1.97x	0.20x	0.19x	0.23x	0.06x	0.17x	0.32x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	3.87M	3.52M	3.31M	3.08M	625K	899K	987K	831K	906K	601K
Long-Term Investments	-179.68M	-219.32M	14.33M	35.93M	695.46M	531.86M	398.46M	60.81M	325.63M	200.17M
Other Non-Current Assets	57K	65K	117.1M	134.2M	32.27M	531.87M	399.27M	278.38M	879K	476K
Total Assets+	326.75M	298.75M	339.85M	441.76M	941.18M	989.99M	946.01M	702.65M	693.97M	602.63M
Asset Turnover	0.04x	0.01x	0.00x	0.04x	0.01x	0.01x	0.01x	0.00x	0.00x	0.01x
Asset Growth %	43.3%	-8.57%	13.76%	29.99%	113.05%	5.19%	-4.44%	-25.72%	-1.23%	-13.16%
Total Current Liabilities+	160.52M	204.08M	273.86M	265.76M	139.2M	180.92M	226.13M	96.89M	51.37M	41.39M
Accounts Payable	2.39M	2.08M	3.39M	4.64M	11.1M	8.87M	11.35M	26.5M	14.64M	5.52M
Days Payables Outstanding	1.18K	482.87	17.44	21.9	47.19	-	37.48	63.46	1.08K	-
Short-Term Debt	4.96M	6.95M	7.46M	12.01M	1.46M	26.45M	5.5M	7.5M	3.7M	4.11M
Deferred Revenue (Current)	87.05M	88.38M	129.01M	30.8M	22.21M	141.61M	31.32M	2.19M	-29.47M	0
Other Current Liabilities	61.29M	97.62M	121.04M	207.08M	92.45M	-529K	152.01M	29.4M	29.64M	27.18M
Current Ratio	1.98x	1.41x	0.72x	0.98x	1.21x	2.29x	2.22x	3.99x	6.76x	9.33x
Quick Ratio	1.98x	1.42x	0.73x	0.98x	1.21x	2.29x	2.10x	3.99x	6.76x	9.33x
Cash Conversion Cycle	-	-	-	-	-	-	186.3	-	-	-
Total Non-Current Liabilities+	2.18M	2.26M	1.99M	9.03M	151.58M	155.53M	135.72M	58.17M	184.37M	153.31M
Long-Term Debt	0	0	0	357K	0	14.82M	14.26M	10.24M	0	0
Capital Lease Obligations	0	0	410K	357K	34.91M	32.09M	29.04M	24.16M	18.25M	14.67M
Deferred Tax Liabilities	0	0	4.4M	6.43M	115.44M	108.63M	89.77M	19.64M	52.46M	0
Other Non-Current Liabilities	1.89M	2.06M	1.42M	876K	0	-1K	2.66M	4.13M	113.66M	138.64M
Total Liabilities	162.7M	206.34M	275.85M	274.79M	290.78M	336.45M	361.86M	155.06M	235.74M	194.7M
Total Debt+	4.96M	6.95M	7.46M	12.37M	39.3M	76.62M	52.75M	46.87M	25.34M	22.36M
Net Debt	-129.8M	-56.01M	-65.19M	-104.68M	-93.06M	-327.26M	-413.68M	-102.99M	-165.74M	-258.28M
Debt / Equity	0.03x	0.08x	0.12x	0.07x	0.06x	0.12x	0.09x	0.09x	0.06x	0.05x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-10.03x	-10.86x	-11.30x	-7.03x	-33.01x	-40.57x	-31.88x	-50.04x	-10.84x	-13.56x
Total Equity+	164.05M	92.41M	64M	166.97M	650.4M	653.54M	584.15M	547.59M	458.23M	407.93M
Equity Growth %	22.71%	-43.67%	-30.75%	160.91%	289.53%	0.48%	-10.62%	-6.26%	-16.32%	-10.98%
Book Value per Share	8.85	4.03	2.68	6.10	22.29	22.32	20.38	19.23	16.58	15.13
Total Shareholders' Equity	226.12M	177.67M	214.3M	275.51M	668.04M	669.75M	593.51M	542.22M	464.07M	414.71M
Common Stock	4.52M	4.61M	4.68M	5.38M	5.41M	5.42M	5.44M	5.46M	5.46M	4.86M
Retained Earnings	-111.42M	-160.34M	-127.87M	-167.69M	254.44M	260.43M	199.87M	149.52M	83.82M	32.49M
Treasury Stock	0	0	0	0	0	0	0	-26.49M	-44.63M	-46.86M
Accumulated OCI	-1.05M	-2.24M	-3.88M	-6.07M	-18.28M	-23.58M	-39.61M	-14.39M	129.15M	133.96M
Minority Interest	-62.07M	-85.25M	-150.31M	-108.53M	-17.64M	-16.21M	-9.37M	5.37M	-5.83M	-6.77M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-28.61M	-58.03M	-88.69M	-72.8M	-98.16M	-131.83M	-158.27M	-178.79M	-105.92M	-134.37M
Operating CF Margin %	-243.71%	-1309.7%	-13644.31%	-444.66%	-1129.79%	-1580.47%	-1586.07%	-8554.64%	-3180.69%	-2783.12%
Operating CF Growth %	-171.37%	-102.83%	-52.82%	17.92%	-34.84%	-34.3%	-20.06%	-12.96%	40.76%	-26.86%
Net Income	-58.24M	-81.61M	-70.7M	-70.66M	366.06M	4.57M	-62.71M	-37.06M	-65.7M	27.78M
Depreciation & Amortization	740K	1.57M	2.1M	2.78M	6.67M	6.64M	7.29M	8.89M	4.93M	3.57M
Stock-Based Compensation	11.1M	10.15M	11.85M	12.64M	14.47M	10.72M	13.95M	14.7M	4.42M	22.85M
Deferred Taxes	-383K	-783K	-116.81M	-19.42M	-546.61M	-151.35M	-112.61M	-70.12M	0	0
Other Non-Cash Items	13.37M	10.7M	81.9M	-8.1M	46.23M	6.11M	-5.05M	-111.12M	-67.09M	-178.34M
Working Capital Changes	4.81M	1.94M	2.97M	9.96M	15.03M	-8.53M	861K	15.92M	17.52M	-10.24M
Change in Receivables	1.11M	581K	-1.67M	467K	747K	-529K	-617K	-7.73M	9.75M	629K
Change in Inventory	0	0	0	0	0	0	-103K	0	0	0
Change in Payables	4.32M	3.52M	5.24M	5.09M	11.17M	605K	8.34M	22.03M	3.84M	-9.7M
Cash from Investing+	-184.24M	-43.23M	83.68M	-39.65M	63.66M	364.48M	197.38M	-107.22M	68.99M	240.89M
Capital Expenditures	-4.61M	-3.68M	-2.17M	-4.49M	-12.54M	-5.42M	-5.66M	-2.18M	-245K	-11K
CapEx % of Revenue	39.27%	82.96%	334%	27.43%	144.31%	65.03%	56.73%	104.11%	7.36%	0.23%
Acquisitions	1.16M	0	-16.34M	-13.39M	-16.04M	-10M	321K	-20.44M	-13.78M	-105.97M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-1.16M	-39.55M	-16.34M	125K	191K	350K	-14.91M	416K	865K	255K
Cash from Financing+	285.94M	29.49M	14.7M	156.89M	49.91M	38.87M	22.73M	-29.83M	78.14M	-16.96M
Debt Issued (Net)	1.48M	2.33M	2.45M	5.96M	1.43M	39.79M	2.21M	393K	-3.34M	-3.39M
Equity Issued (Net)	0	0	1000K	-35K	1000K	1000K	-1000K	-1000K	-1000K	-1000K
Dividends Paid	0	0	-91K	-8K	-112K	0	0	0	0	0
Share Repurchases	0	0	-66K	-35K	-1.28M	0	0	-26.49M	-19.65M	-107.56M
Other Financing	284.46M	27.16M	0	150.96M	-1.68M	-2.91M	33.84M	-4.07M	99.98M	93.1M
Net Change in Cash	72.79M	-71.79M	9.69M	44.4M	15.31M	271.52M	61.83M	-315.84M	41.22M	89.56M
Free Cash Flow+	-33.22M	-61.71M	-90.86M	-77.29M	-110.69M	-137.25M	-163.94M	-180.97M	-106.16M	-134.38M
FCF Margin %	-282.97%	-1392.67%	-13978.31%	-472.09%	-1274.1%	-1645.5%	-1642.8%	-8658.76%	-3188.05%	-2783.35%
FCF Growth %	-203.03%	-85.75%	-47.24%	14.94%	-43.23%	-23.99%	-19.44%	-10.39%	41.34%	-26.58%
FCF per Share	-1.79	-2.69	-3.80	-2.82	-3.79	-4.69	-5.72	-6.36	-3.84	-4.98
FCF Conversion (FCF/Net Income)	0.73x	1.19x	-2.87x	1.67x	-0.23x	-22.03x	2.61x	3.55x	1.61x	-2.51x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-26.46%	-38.05%	39.47%	-37.8%	103.05%	0.92%	-9.79%	-8.9%	-13.06%	12.36%
Return on Invested Capital (ROIC)	-95.55%	-156.94%	-491.73%	-255.4%	-32.78%	-20.29%	-45.31%	-48.18%	-29.75%	-46.17%
Gross Margin	93.7%	64.57%	-10828.46%	-372.8%	-888.12%	100%	-1007.03%	-6546.17%	-48.14%	26.04%
Net Margin	-335.55%	-1101.15%	4749.08%	-266.65%	4847.42%	71.75%	-606.85%	-2409.33%	-1972.88%	1108.33%
Debt / Equity	0.03x	0.08x	0.12x	0.07x	0.06x	0.12x	0.09x	0.09x	0.06x	0.05x
Interest Coverage	-10.03x	-10.86x	-11.30x	-7.03x	-33.01x	-40.57x	-31.88x	-50.04x	-10.84x	-13.56x
FCF Conversion	0.73x	1.19x	-2.87x	1.67x	-0.23x	-22.03x	2.61x	3.55x	1.61x	-2.51x
Revenue Growth	483.5%	-62.26%	-85.33%	2418.62%	-46.93%	-3.99%	19.64%	-79.06%	59.33%	44.98%

PureTech Health plc (PRTC) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare PRTC vs Peers

vs REGN

vs CNTA

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

PureTech Health plc (PRTC) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare PRTC vs Peers

vs REGN

vs CNTA

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios